UNSPSC 51331602: Lometraline

This classification denotes an anticonvulsant agent with the molecular formula C13H18CLNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V78B234QEY chemically known as 1-naphthalenamine, 8-chloro-1,2,3,4-tetrahydro-5-methoxy-n,n-dimethyl- but generally known as lometraline, which bears US NIH Compound Identifier 34789. European Medicines Agency schedules Lometraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08563MIG.

UNSPSC 51331602 Lometraline is a Commodity-tier code that nominally designates a specific pharmaceutical active ingredient, though recent state and local solicitations tagged under this code do not focus on lometraline itself but rather on broader pharmaceutical procurement — naloxone distribution systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements. State and local governments buying under this code are procuring emergency response medications, pharmacy benefit management infrastructure, and commodity drug supplies through health departments, cooperative purchasing alliances, and HHS agencies. Issuing bodies include county health departments, state HHS commissions, and multistate cooperative purchasing vehicles (MMCAP), indicating that pharmaceutical procurement spans individual jurisdictions as well as consolidated regional and statewide arrangements that distribute contracts across multiple participating states and localities.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date); the contract includes a two-year initial term plus one-year renewal option and potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline; this cooperative procurement spans Minnesota, Oregon, and other participating jurisdictions and requires vendors to work through three authorized wholesalers (AmerisourceBergen / Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026.